ORGS (Orgenesis) Accounts Payable & Accrued Expense: $18.37 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORGS Orgenesis Inc ORGS
12 GF Score
Price $0.45
View Full Analysis

What is Orgenesis Accounts Payable & Accrued Expense?

Orgenesis ORGS +9.12% 12 Accounts Payable & Accrued Expense is $18.37 Mil as of Dec. 2024. GuruFocus rates ORGS with a GF Score™ of 12/100.

Orgenesis's quarterly accounts payable & accrued expense increased from Jun. 2024 ($18.60 Mil) to Sep. 2024 ($19.36 Mil) but then declined from Sep. 2024 ($19.36 Mil) to Dec. 2024 ($18.37 Mil).

Orgenesis's annual accounts payable & accrued expense increased from Dec. 2022 ($9.23 Mil) to Dec. 2023 ($10.67 Mil) and increased from Dec. 2023 ($10.67 Mil) to Dec. 2024 ($18.37 Mil).

Orgenesis Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Orgenesis's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Accounts Payable & Accrued Expense Chart

Orgenesis Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.91 7.68 9.23 10.67 18.37

Orgenesis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.67 22.83 18.60 19.36 18.37
ORGS
12GF Score
Orgenesis Inc ORGS
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orgenesis Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $18.37 Mil mean?
Orgenesis (ORGS) has a Accounts Payable & Accrued Expense of $18.37 Mil as of Dec. 2024. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Orgenesis and its competitors.
Is Orgenesis' Accounts Payable & Accrued Expense too high?
Orgenesis' current Accounts Payable & Accrued Expense is $18.37 Mil. Overall, Orgenesis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Orgenesis' Accounts Payable & Accrued Expense compare to ENDV and GBLX?
Orgenesis' Accounts Payable & Accrued Expense of $18.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Orgenesis and its competitors. Orgenesis's current Accounts Payable & Accrued Expense is $18.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orgenesis stock overvalued right now?
Orgenesis (ORGS) has a current Accounts Payable & Accrued Expense of $18.37 Mil. The current Accounts Payable & Accrued Expense is $18.37 Mil. Orgenesis' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Orgenesis (ORGS), the current Accounts Payable & Accrued Expense is $18.37 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Orgenesis Business Description

Address 20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.
12GF Score

Get the complete analysis for ORGS

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price